Académique Documents
Professionnel Documents
Culture Documents
eart failure is a common condition affecting 12% of the population. The incidence rises with age in both men and women (Mehta and Cowie, 2006). The mean age at diagnosis is around 74years of age (Cowie et al, 1997; Mehta and Cowie, 2006). Regardless of aetiology, heart failure is associated with a worse quality of life than many other common chronic illnesses such as chronic obstructive pulmonary disease, arthritis, depression and other cardiovascular disease (Hobbs et al, 2002). Survival and quality of life worsen as patients reach the advanced phase of heart failure (Hobbs et al, 2002). The European Society of Cardiology defines advanced heart failure as a chronic condition in which patients are persistently restricted in performing their activities of daily living (New York Heart Association (NYHA) functional class III or IV) despite best medical therapy, with evidence of impaired cardiac function (left ventricular ejection fraction <30%) (Metra et al, 2007). Patients with advanced heart failure and reduced left ventricular ejection fraction should be treated with evidence-based therapy including angiotensin-converting enzyme inhibitors, beta-blockers and aldosterone antagonists together, when appropriate, with cardiac resynchronization therapy and an implantable defibrillator (McMurray et al, 2012). Despite such treatment, in many patients heart failure is a progressive condition with worsening symptoms and deteriorating functional capacity. For a subgroup of such patients, heart transplantation or mechanical circulatory support may improve symptoms, quality life and survival. This article describes factors important in case selection for heart transplantation and emphasizes the importance of referral before serious complications have developed.
Dr Owais Dar is Speciality Registrar and Advanced Heart Failure Fellow, Royal Brompton & Harefield NHS Foundation Trust, Harefield Hospital, London and Dr Nicholas R Banner is Consultant in Cardiology, Transplant Medicine and Circulatory Support, Royal Brompton & Harefield NHS Foundation Trust, Harefield Hospital, Harefield, Middlesex UB9 6JH and Honorary Senior Lecturer in the Institute of Cardiovascular Medicine and Science, National Heart and Lung Institute, Imperial College, London Correspondence to: Dr NR Banner (n.banner@rbht.nhs.uk)
The first UK heart transplant occurred in 1968 and the first UK heart transplant programme was established in 1979. Currently there are six adult heart transplant centres (Birmingham, Glasgow, Harefield, Manchester, Newcastle, and Papworth). The number of heart transplants reached a peak of approximately 300 transplants per year in the 1990s. Subsequently there has been a decline in activity with an average of 131 transplants per year between 2009 and 2012 (NHS Blood and Transplant, 2013). In contrast, the number of people on the heart transplant waiting list has increased from 92 in March 2009 to 194 in December 2012 (NHS Blood and Transplant, 2013). These trends have been attributed to a decreased availability of donor hearts suitable for transplantation. Currently approximately 31% (19 million) of the UK population are on the organ donor register (NHS Blood and Transplant, 2013). Limited donor availability means that the average time spent on the waiting list for a non-urgent heart transplant between 2007 and 2010 was 253days (NHS Blood and Transplant, 2013). Potential candidates for heart transplantation are assessed by a multidisciplinary team involving heart failure cardiologists, cardiac surgeons, specialist nurses, radiologists and psychologists with input from other specialties including palliative care. The decision to recommend transplantation is made by weighing the risks and benefits of surgery against those of ongoing medical treatment. The scarcity of donor hearts requires additional consideration of how to maximize the overall benefit from the hearts that are available for transplantation. The timing of intervention is crucial. Late referral when patients have developed complications of advanced heart failure increases the risks of and may potentially contraindicate transplantation. Although heart transplantation has never been subject to a clinical trial, statistical modeling has demonstrated that it improves survival in advanced heart failure (Banner et al, 2008; NHS Blood and Transplant, 2013), and improves quality of life and patients ability to carry out activities of daily living (Almenar-Pertejo et al, 2006). In the UK post-transplant survival is 86.9% at 30days, 80.8% at 1year and 70.8% at 5years (NHS Blood and Transplant, 2013).
British Journal of Hospital Medicine, May 2013, Vol 74, No 5
Cardiac transplantation
258
The commonest indications for adult heart transplantation are left ventricular systolic dysfunction secondary to non-ischaemic dilated cardiomyopathy and ischaemic cardiomyopathy (Stehlik et al, 2010; Thekkudan et al, 2010). Other less common causes include valvular heart disease with poor ventricular function and infiltrative cardiomyopathy (such as amyloidosis, sarcoidosis or giant
259
Absolute and relative contraindications to heart transplantation are shown in Tables 3 and 4. Many relative contraindications that, in isolation, may not preclude transplantation can become an absolute contraindication when present in combination (Banner et al, 2011). Although age is not an absolute contraindication, increasing age is a risk factor (Stehlik et al, 2010). In practice very few patients have been transplanted over the age of 65years in the UK and the average age of heart transplant recipients internationally is around 50years (Stehlik et al, 2010), considerably younger than that in the unselected population of heart failure patients (Cowie et al, 1997).
Contraindications to transplantation
A left ventricular assist device is an electrically powered mechanical pump which is connected to the left ventricle
260
plantation is not considered to be cost-effective by standard NHS criteria. Despite this, the scarcity of suitable donor hearts has led to a growing population of left ventricular assist device patients receiving long-term support while awaiting a transplant. In some patients with non-ischaemic dilated cardiomyopathy, left ventricular function can improve during left ventricular assist device support and concomitant heart failure drug therapy, thereby allowing explantation of the left ventricular assist device without transplantation and a return to long-term medical therapy (Birks et al, 2011). Not all patients are suitable candidates for left ventricular assist device support, e.g. patients with predominant right ventricular failure, restrictive or hypertrophic cardiomyopathy, those who have undergone multiple previous cardiac operations or who have prosthetic heart valve replacements (particularly aortic). It is especially important that such patients are referred at a stage when they will be able to wait long enough to receive a transplant and before heart failure complications have developed which preclude transplantation. Many of the factors that increase the risk of heart transplant surgery are also risk factors for left ventricular assist device implantation (e.g. sepsis, renal dysfunction, liver dysfunction, coagulopathy, respiratory failure and age over 65years) (Wilson et al, 2009).
Patients referred in a very advanced stage of heart failure usually have complications that may prevent transplantation, particularly cardiorenal syndrome, group 2 pulmonary hypertension and hepatic dysfunction. Renal failure is a risk factor for all forms of cardiac surgery (Nashef et al, 1999) including transplantation (Stehlik et al, 2010). It is also a risk factor for chronic kidney disease after transplantation (Stehlik et al, 2010). Investigations are required to look for intrinsic renal disease or systemic disease affecting the kidneys including diabetes with complications. When appropriate, the transplant centre will look for evidence that the renal dysfunction is at least partially reversible following a temporary withdrawal of angiotensin-converting enzyme inhibitors and treatment with inotropes to improve cardiac output. However, renal function that remains below acceptable limits may be a contraindication to transplant listing. Similarly, increased pulmonary vascular resistance as a complication of prolonged pulmonary hypertension caused by left heart failure is a risk factor for heart transplantation because it may lead to failure of the donor right ventricle immediately after surgery. Patients who have elevated pulmonary vascular resistance need investigation to determine whether this can be reversed pharmacologically. Irreversible pulmonary hypertension is a contraindication to transplantation. Patients with revers261
Conclusions
KEY POINTS
n Despite optimal medical therapy, advanced chronic heart failure is usually a progressive disease and patients have a poor prognosis and quality of life. n Heart transplantation is by far the most effective therapy for such patients, improving longevity and quality of life. n It is important that patients who are potential candidates for transplantation should be referred before the complications of advanced heart failure such as pulmonary hypertension, cardiorenal syndrome or liver failure have developed and become a potential barrier to transplantation.
262
TRAINEE SURGEONS
Patient Care in Cardiac Surgery
TRAINEE ANAESTHETISTS Incorporates a CD ROM with animations illustrating some of the more PERFUSIONISTS CRITICAL CARE THERAPISTS pertinent points of the text CRITICAL CARE NURSES Briefing is based on the authors extensive experience in training a variety of individuals in the cardiac operating theatre Features excellent full colour illustrations, flow charts and other learning features
About this book This Brieng, and the style in which it is written, is based upon the authors extensive experienc e in training a variety of individuals in the cardiac operating theatre. So it has been created in a way which should appeal not only to trainee anaesthetists, but also to other involved clinical staff which include trainee surgeons, perfusion ists, anaesthetic support staff, ward nurses, theatre nurses and critical care nurses and therapists involved in the care of cardiac surgical patients.
ISBN-13: 978-1-85642-335-9; 234 x 156 mm; paperback; 204 pages; publication March Dr Chris Aps has been a consultan t cardiac anaesthetist at St Thomas Hospital, London for over 20 years. He has huge 2007; 24.99 experience in hands-on training of trainee doctors in cardiac
anaesthesia and in-theatre teaching for undergraduates, nurses, and all clinical staff with an interest in patients undergoing cardiac surgery.
ISBN 978-1-85642-335-9
by Chris Aps
CD ROM included
781856 423359
www.quaybooks.co.uk
by Chris Aps
19/3/07 15:20:01
CardiacRe-sized2.indd 1
www.quaybooks.co.uk
263
Copyright of British Journal of Hospital Medicine (17508460) is the property of Mark Allen Publishing Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.